In advancing healthcare and addressing unmet medical needs, regulatory bodies play a crucial role in incentivizing the development of therapies for rare diseases. The Saudi Food and Drug Authority (SFDA) has made significant strides in this direction by introducing an Orphan Drug Designation (ODD) framework into the drug registration process.

Orphan drugs are pharmaceuticals developed to treat diseases that affect a small number of people in a population. Recognizing the unique challenges sponsors face in developing and approving these drugs, regulatory authorities worldwide, including the SFDA, have established specific guidelines to facilitate their development and approval.

Definition of Orphan Drug Status

SFDA provides clear criteria for determining whether a drug qualifies for orphan status. Generally, this involves demonstrating that the drug’s indication is to treat a rare disease or condition affecting a limited number of individuals.

Eligibility Criteria

One indication, or an orphan condition.
An Unregistered drug in the SFDA
Already Registered drug in SFDA with:
- A new dosage form or
- New orphan condition or
- Any major variation that meets the ODD conditions.
Seriously debilitating diseases or life-threatening conditions or diseases.
Prevalence of rare disease or condition, or lack of financial viability.
Under development for this orphan condition.
Comparison with other methods for diagnosing, preventing, or treating the condition.

The authority allows one ODD application submission for either one orphan indication or one orphan condition per drug, or one orphan indication per dosage form, with consideration of intellectual property. Separate designation applications need to be submitted for each orphan indication.

Timings of Submission

A sponsor can apply for ODD at any stage of the development before submitting the application for marketing authorization.

Incentives for Orphan Drugs

The SFDA recognizes the challenges faced by orphan drug sponsors and offers incentives to encourage their development. These incentives may include:

Priority review
Pre-submission meetings
Scientific and regulatory advice and consultation by the SFDA’s drug sector
Pricing as per the SFDA rules of pricing

ODD Application Process

Sponsors seeking SFDA orphan drug designation must submit a comprehensive application that includes detailed information about the drug, the rare disease it aims to treat, and evidence supporting its potential benefits. The SFDA reviews these applications meticulously to ensure that the criteria for orphan status are met.

Post-Approval Monitoring

Once a drug receives orphan designation and subsequently gains approval, the SFDA continues to monitor its safety and efficacy. As part of the pharmacovigilance system, this post-approval surveillance ensures ongoing compliance with regulatory standards and provides additional reassurance to patients and healthcare providers.

Impact on Rare Disease Patients

The SFDA’s orphan drug designation program holds great promise for individuals affected by rare diseases in Saudi Arabia. By providing a supportive regulatory environment and incentivizing the development of orphan drugs, the SFDA helps expand treatment options and ultimately improves the quality of life for those facing rare, often debilitating conditions.

Conclusion

In the complex drug development landscape, the SFDA’s commitment to orphan drugs stands as a beacon of hope for those with rare diseases. The guidelines for orphan drug designation create a pathway for sponsors to navigate the challenges of rare conditions, fostering innovation and bringing new treatments to those who need them most.

As the SFDA continues to refine and adapt its regulatory framework, the future promises more breakthroughs and advancements in rare disease therapeutics, offering renewed hope and healing to individuals and families across Saudi Arabia.

Registration Support

Pharmaknowl provides expert regulatory guidance from ODD eligibility assessment through submission, helping you achieve efficient and compliant ODD designation approval. Partner with us to simplify your regulatory journey.

Madiha Baaj

Regulatory Affairs Specialist, experienced in pharmaceutical regulatory activities, including product registration, renewals, and variations. Skilled in preparing and managing regulatory submissions & pathways such as Orphan Drug Designation (ODD), Breakthrough Therapy, and Priority Review.

Resources